AflacLL1901 (CHOA-AML)

Phase 2 Terminated 8 enrolled Emory University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.

Timeline

Start: 2020-01-24
Primary completion: 2022-03-15
Completion: 2022-03-15

Publications

Sabnis HS, Minson KA, Monroe C, Allen K, Metts JL, Cooper TM, Woods WG, Castellino SM, Keller FG. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Leuk Res. 2020 Sep;96:106421. doi: 10.1016/j.leukres.2020.106421. Epub 2020 Jul 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Asparaginase Erwinia chrysanthemi	Protein / enzyme biologic	25000 iu	Intramuscular
Subject	Cytarabine	Small molecule	100 mg/m2	Intravenous
Subject	Daunorubicin	Small molecule	50 mg/m2	Intravenous
Subject	Etoposide	Small molecule	150 mg/m2	Intravenous
Subject	Gemtuzumab Ozogamicin	Monoclonal antibody	3 mg/m2	—
Subject	Sorafenib	Small molecule	200 mg/m2	—

AflacLL1901 (CHOA-AML)

Summary

Timeline

Publications

Drugs

Indications